Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer
Fifth Cambridge Conference - June 2005
This program was based on a conference of multidisciplinary leaders in breast cancer research and clinical care. The focus of the program was on basic and clinical research related to new endocrine agents.
This educational program was directed by Aman U. Buzdar, MD, MD Anderson Cancer Center, Steven E. Come, MD, Beth Israel Deaconess Medical Center, Carlos L. Arteaga, MD, Vanderbilt-Ingram Cancer Center, James N. Ingle, MD, Mayo Clinic, and Stephen RD Johnston, MD, PhD, FRCP, Royal Marsden Hospital.
Educational Objectives
1) Understand current concepts of estrogen receptor function and its role and interactions between estrogen and non-estrogen cellular pathways in breast cancer biology; 2) discuss mechanisms of action of present endocrine therapies and mechanisms of resistance to treatment; 3) describe the use and sequence of endocrine therapies in breast cancer prevention in early and advanced disease; and 4) assess directions for future research in breast cancer prevention and treatment, including new targets and combinations with endocrine therapies.
Educational Grant Support
The program was supported by educational grants provided by: Pfizer Oncology, Novartis Pharmaceuticals, Genentech and Genomics Health.
Sponsorship
CME sponsorship and program management were provided by InforMEDical.
The conference proceedings were published as a peer-reviewed educational supplement to Clinical Cancer Research, February 1, 2006, Vol 12 (3 Suppl), 997s-1068s.
The CME activity based on the publication was effective February 2006 through January 2008.
Journal Website
(subscription may be required to access full journal supplement)
